Lilly’s Retatrutide Shows 1.9% A1c Drop, Trailing Mounjaro in Phase 3

Eli Lilly has released the first Phase 3 data for retatrutide, its highly anticipated 'triple-G' agonist, marking a critical milestone in the company's metabolic pipeline. The drug, which targets GLP-1, GIP, and glucagon receptors, demonstrated a blood sugar (HbA1c) reduction of up to 1.9% in patients with type 2 diabetes. While this performance comfortably clears the bar for clinical relevance and regulatory approval, it has sparked immediate comparisons with Lilly’s existing blockbuster, Mounjaro (tirzepatide), which achieved reductions as high as 2.6% in its own pivotal SURPASS trials. This slight 'lag' in glucose-lowering efficacy suggests that retatrutide’s primary value proposition may lie elsewhere—specifically in its potential to set a new ceiling for weight loss.

The inclusion of the glucagon receptor in retatrutide’s mechanism is intended to increase energy expenditure, a distinct approach from the dual-agonist mechanism of Mounjaro. In Phase 2 trials, retatrutide demonstrated weight loss of approximately 24% over 48 weeks, a figure that exceeds the roughly 21-22% seen with Mounjaro and Zepbound. The latest Phase 3 diabetes data, while slightly lower on the A1c metric, does not necessarily diminish the drug's blockbuster potential. Instead, it reinforces the strategy of portfolio segmentation, where Mounjaro remains a potent tool for glycemic control while retatrutide is positioned as the 'heavy hitter' for patients where massive weight reduction is the primary clinical goal.

“

In Phase 2 trials, retatrutide demonstrated weight loss of approximately 24% over 48 weeks, a figure that exceeds the roughly 21-22% seen with Mounjaro and Zepbound.

From a competitive standpoint, Lilly is effectively racing against its own benchmarks to maintain a dominant share of the incretin market. The metabolic space is becoming increasingly crowded, with Novo Nordisk developing CagriSema—a combination of semaglutide and cagrilintide—and several mid-cap biotech firms advancing their own multi-agonists. By advancing retatrutide into late-stage trials, Lilly is building a multi-layered defense against competitors, ensuring that even if Mounjaro faces pricing pressure or patent expirations in the future, a more potent successor is already in the wings.